De-Escalation Therapy for Human Papillomavirus Negative Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 26, 2019

Primary Completion Date

November 1, 2023

Study Completion Date

November 1, 2023

Conditions
Human Papilloma VirusSquamous Cell CarcinomaSquamous Cell Carcinoma of the Head and NeckHPV-Related Squamous Cell CarcinomaHNSCC
Interventions
DRUG

Carboplatin

Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.

DRUG

Paclitaxel

"During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles.~During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy."

DRUG

Nivolumab

Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.

RADIATION

Radiation

Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13

DRUG

Hydroxyurea Pill

One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle

DRUG

5-fluorouracil

5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles

DRUG

Filgrastim Injection

Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.

DRUG

Cisplatin

Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.

Trial Locations (1)

60637

University Of Chicago Medicine Comprehensive Cancer Center, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT03944915 - De-Escalation Therapy for Human Papillomavirus Negative Disease | Biotech Hunter | Biotech Hunter